News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ISTO Technologies, Inc. to Present at the Canaccord Adams Musculoskeletal Conference


2/16/2010 1:06:06 PM

ST. LOUIS, MO--(Marketwire - February 16, 2010) -

ISTO Technologies, Inc. announced today that it will participate in the 2010 Canaccord Adams Musculoskeletal Conference to be held at the Sheraton New Orleans Hotel on Tuesday, March 9, 2010. Mitchell Seyedin, Ph.D., President and CEO, is scheduled to provide an overview of the Company at 8:20 a.m. Central Time. The conference, directly preceding the 2010 American Academy of Orthopedic Surgeons Annual Meeting, will showcase a diverse group of public and private companies in the areas of orthopedics, biologics, dental implants, ENT, imaging, robotic surgery, tissue sculpting, and regenerative medicine.

ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sports medicine applications.

The Company's leading cartilage regeneration product, DeNovo® ET, is a scaffold-free engineered cartilage tissue derived from expanded juvenile chondrocytes and is currently in human clinical trials for the repair of injured knee joints as an investigational product.

ISTO's second cell-based product in development, NuQu™, is an injectable formulation of juvenile cartilage cells intended for regeneration and repair of tissue lost to chronic disc diseases. NuQu is intended for minimally invasive intervention for patients suffering from discogenic back pain. ISTO has received IND approval from the FDA to commence with a Phase I clinical trial for NuQu, which is scheduled to start in early 2010.

In addition to ISTO's clinical-stage cell-based cartilage programs, the company is currently producing and selling, InQu®, an osteobiologic bone graft extender and substitute. The primary target market for the product is spinal fusion applications. InQu is a biologic bone grafting material with integrated hyaluronic acid and a synthetic polymer representing a new class of biomaterials for better handling and biology.

About ISTO

ISTO Technologies, Inc. is developing and marketing clinical solutions for sports medicine applications and spinal therapies. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage, discs and bone. For additional information on ISTO, please visit our website at www.istotech.com or contact Scott Gill, Chief Financial Officer, at 314-995-6049.


Contact:
Scott Gill
Chief Financial Officer
314-995-6049
www.istotech.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES